|
Jul 14
|
Novartis AG (VTX:NOVN) On An Uptrend: Could Fundamentals Be Driving The Stock?
|
|
Jul 13
|
What To Expect in Markets This Week: Big Bank Earnings, June Inflation, Retail Sales Data
|
|
Jul 12
|
FDA willing to trade faster drug reviews for lower prices, Bloomberg reports
|
|
Jul 11
|
Portfolio manager sees long-term AI upside in healthcare sector
|
|
Jul 11
|
Sector Update: Health Care Stocks Retreat Late Afternoon
|
|
Jul 11
|
Bayer Wins Hormone-Free Treatment Approval for Women in the UK
|
|
Jul 11
|
Stocks to watch this week: Goldman Sachs, Netflix, TSMC, ASML and Burberry
|
|
Jul 10
|
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS)
|
|
Jul 10
|
Alcohol Related Liver Disease Market Forecast, 2025-2035 | Personalized Medicine Transforming ARLD Treatment Landscape
|
|
Jul 10
|
Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump
|
|
Jul 10
|
Renasant Bio, chasing drugs for ADPKD, raises $55M in seed funding
|
|
Jul 9
|
$14 Billion Cell and Gene Therapy Market to Double by 2030, Driven by Oncology and RNA Breakthroughs, reports Kalorama Information
|
|
Jul 9
|
Sironax Grants Novartis Exclusive Option to Acquire its Brain Delivery Platform While Retaining Rights to Advance Selected Therapeutic Assets
|
|
Jul 9
|
Trump's Drug Tariffs: Where Does the U.S. Import Pharmaceuticals From?
|
|
Jul 9
|
As its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing
|
|
Jul 8
|
Finally: A malaria drug made just for babies has been approved—here’s why it matters
|
|
Jul 8
|
Ascentage Pharma Names CFO & SVP of Global Corporate Development & Finance
|
|
Jul 8
|
Novartis Gets Swiss Approval for Malaria Drug for Infants
|
|
Jul 8
|
Swissmedic approves Novartis’ malaria medicine for babies
|
|
Jul 1
|
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?
|